JP2005529603A - 糖尿病を予防、治療、および診断するための組成物および方法 - Google Patents

糖尿病を予防、治療、および診断するための組成物および方法 Download PDF

Info

Publication number
JP2005529603A
JP2005529603A JP2004512780A JP2004512780A JP2005529603A JP 2005529603 A JP2005529603 A JP 2005529603A JP 2004512780 A JP2004512780 A JP 2004512780A JP 2004512780 A JP2004512780 A JP 2004512780A JP 2005529603 A JP2005529603 A JP 2005529603A
Authority
JP
Japan
Prior art keywords
seq
smap
polypeptide
agent
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004512780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529603A5 (enExample
Inventor
ションナ ムーディー
トーマス エー． グスタフソン
チ−ワイ ワン
Original Assignee
メタボレックス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボレックス インコーポレーティッド filed Critical メタボレックス インコーポレーティッド
Publication of JP2005529603A publication Critical patent/JP2005529603A/ja
Publication of JP2005529603A5 publication Critical patent/JP2005529603A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004512780A 2002-06-13 2003-06-13 糖尿病を予防、治療、および診断するための組成物および方法 Pending JP2005529603A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38871602P 2002-06-13 2002-06-13
PCT/US2003/018976 WO2003105879A1 (en) 2002-06-13 2003-06-13 Compositions and methods for preventing, treating and diagnosing diabetes

Publications (2)

Publication Number Publication Date
JP2005529603A true JP2005529603A (ja) 2005-10-06
JP2005529603A5 JP2005529603A5 (enExample) 2006-07-27

Family

ID=29736528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004512780A Pending JP2005529603A (ja) 2002-06-13 2003-06-13 糖尿病を予防、治療、および診断するための組成物および方法

Country Status (5)

Country Link
US (1) US20060210974A1 (enExample)
EP (1) EP1511506A4 (enExample)
JP (1) JP2005529603A (enExample)
AU (1) AU2003238232A1 (enExample)
WO (1) WO2003105879A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069885A2 (en) * 1999-05-14 2000-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
WO2001066738A2 (en) * 2000-03-06 2001-09-13 Eli Lilly And Company Nucleic acids, encoding human crsp1 and uses thereof

Also Published As

Publication number Publication date
EP1511506A4 (en) 2006-12-06
US20060210974A1 (en) 2006-09-21
EP1511506A1 (en) 2005-03-09
AU2003238232A1 (en) 2003-12-31
WO2003105879A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
US20080064857A1 (en) Methods and Reagents for Diagnosis and Treatment of Diabetes
JP2005535302A (ja) 糖尿病およびインスリン抵抗性の診断および治療のための方法
JP2008503212A (ja) 肥満、糖尿病およびインスリン抵抗性の診断および治療の方法
US7053180B2 (en) Isolated islet beta-cell two-pore domain potassium channel
US20060228706A1 (en) Methods of diagnosing and treating diabetes and insulin resistance
JP2005529603A (ja) 糖尿病を予防、治療、および診断するための組成物および方法
JP2008506949A (ja) 肥満、糖尿病およびインスリン抵抗性の診断および治療の方法
JP2006503265A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
JP2005528921A (ja) Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法
US7144985B2 (en) Methods and reagents for diagnosis and treatment of diabetes
US20080318312A1 (en) Pancreatic islet transcription factor and uses thereof
US7510851B2 (en) Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
US20060234292A1 (en) Methods of diagnosing and treating diabetes and insulin resistance
JP2006507799A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
JP2008505648A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
JP2008502909A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
US20050208516A1 (en) Methods and reagents for diagnosis and treatment of diabetes
AU2004304917A1 (en) Genes commonly regulated by different classes of antidepressants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060607

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091112